Table 1.
Patient characteristics
| Characteristics | ZA (n = 350) | Denosumab (n = 402) |
ZA-to-denosumab (n = 43) |
|---|---|---|---|
| Male sex, n (%) | 175 (50.0%) | 222 (55.2%) | 13 (30.2%) |
| Age (years), median (IQR) | 68 (60–75) | 69 (61–75) | 61 (53–68) |
| Type of disease, n (%) | |||
| Lung cancer | 85 (24.3%) | 183 (45.5%) | 13 (30.2%) |
| Breast cancer | 43 (12.3%) | 86 (21.4%) | 20 (46.5%) |
| Multiple myeloma | 120 (34.3%) | 6 (1.5%) | 3 (7.0%) |
| Prostate cancer | 34 (9.7%) | 83 (20.7%) | 3 (7.0%) |
| Others | 68 (19.4%) | 44 (11.0%) | 4 (9.3%) |
| Tooth extraction before starting BMAs, n (%) | 74 (21.1%) | 92 (22.9%) | 8 (18.6%) |
| Comorbid with diabetes, n (%) | 62 (17.7%) | 74 (18.4%) | 7 (16.3%) |
| Concomitant medication, n (%) | |||
| Antiangiogenic agents a | 61 (17.4%) | 102 (25.4%) | 23 (53.5%) |
| Corticosteroids | 31 (8.9%) | 58 (14.4%) | 6 (14.0%) |
| Tooth extraction after starting BMAs, n (%) | 30 (8.6%) | 36 (9.0%) | 4 (9.3%) |
| Number of treatment courses, median (IQR) | |||
| Zoledronic acid | 6 (3–16) | 0 | 8 (2–17) |
| Denosumab | 0 | 8 (3–17) | 8 (3–19) |
For continuous values, data are presented as the median [interquartile range (IQR)]
BMA bone-modifying agent, MRONJ medication-related osteonecrosis of the jaw, ZA zoledronic acid
aIncludes axitinib, bevacizumab, everolimus, lenvatinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib, and temsirolimus